3,5-Dibromo-α-(2-methoxyphenyl)benzenemethanol | 161778-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-Dibromo-α-(2-methoxyphenyl)benzenemethanol
• 英文别名: (3,5-Dibromophenyl)-(2-methoxyphenyl)methanol
• CAS: 161778-01-4
• 化学式: C₁₄H₁₂Br₂O₂
• 分子量: 372.056
• InChiKey: MECWZUPDZXQPGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-Dibromo-α-(2-methoxyphenyl)benzenemethanol 在 palladium on activated charcoal 吡啶 、 4-二甲氨基吡啶 、 palladium diacetate 、 ammonium hydroxide 、 sodium hydroxide 、 sodium hypochlorite 、 草酰氯 、 氢气 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 乙醇 、 乙酸乙酯 、 乙腈 为溶剂， 生成 3-[3-[2-(4-Chloro-benzenesulfonylamino)-ethyl]-5-(2-methoxy-benzyl)-phenyl]-propionic acid
  参考文献：
  名称：

  Thromboxane modulating agents. 4. Design and synthesis of 3-(2-[{(4-chlorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid derivatives as potent thromboxane receptor antagonists

  摘要：

  The design of a series of thromboxane receptor antagonists based on 3-(2-[{(4-chlorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid (1) is described. Addition of an arylmethyl group at the 5-position of 1 gave exceptionally potent agents in vitro and in vivo, with 13a (UK-147,535) giving complete blockade of the TxA(2) receptor for greater than 12 hours in dogs, following all oral dose of 0.1 mg/kg. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00242-x
• 作为产物：
  描述：

  1,3,5-三溴苯 、 邻甲氧基苯甲醛 在 正丁基锂 作用下， 生成 3,5-Dibromo-α-(2-methoxyphenyl)benzenemethanol
  参考文献：
  名称：

  Thromboxane modulating agents. 4. Design and synthesis of 3-(2-[{(4-chlorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid derivatives as potent thromboxane receptor antagonists

  摘要：

  The design of a series of thromboxane receptor antagonists based on 3-(2-[{(4-chlorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid (1) is described. Addition of an arylmethyl group at the 5-position of 1 gave exceptionally potent agents in vitro and in vivo, with 13a (UK-147,535) giving complete blockade of the TxA(2) receptor for greater than 12 hours in dogs, following all oral dose of 0.1 mg/kg. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00242-x

文献信息

• Benzenealkanoic acids for cardiovascular diseases
  申请人：Pfizer Inc.

  公开号：US05618941A1

  公开（公告）日：1997-04-08

  Compounds of formula (I) wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each H or C.sub.1 -C.sub.4 alkyl; R.sup.5 is (CH.sub.2).sub.m NHSO.sub.2 R.sup.6 or (CH).sub.m NHCOR.sup.6 ; R.sup.6 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl optionally substituted by aryl, aryl or heteroaryl; R.sup.7 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, CF.sub.3, OCF.sub.3, CN, CONH.sub.2, or S(O).sub.n (C.sub.1 -C.sub.4 alkyl); X is CH.sub.2, CHCH.sub.3, CH(OH), C(OH)CH.sub.3, C.dbd.CH.sub.2, CO or O; m is 0 or 1 and n is 0, 1 or 2, and their pharmaceutically acceptable salts and biolabile esters, are antagonists of thromboxane A.sub.2 of utility, particulary in combination with a thromboxane synthetase inhibitor, in the treatment of atherosclerosis and unstable angina and for prevention of reocclusion after percutaneous transluminal angioplasty.

  式(I)中的化合物，其中R.sup.1、R.sup.2、R.sup.3和R.sup.4分别为H或C.sub.1 -C.sub.4烷基；R.sup.5为(CH.sub.2).sub.m NHSO.sub.2R.sup.6或(CH).sub.m NHCOR.sup.6；R.sup.6为C.sub.1 -C.sub.6烷基，C.sub.3 -C.sub.6环烷基，可选择地被芳基，芳基或杂环烷基取代；R.sup.7为H，C.sub.1 -C.sub.4烷基，C.sub.1 -C.sub.4烷氧基，卤素，CF.sub.3，OCF.sub.3，CN，CONH.sub.2或S(O).sub.n(C.sub.1 -C.sub.4烷基)；X为CH.sub.2，CHCH.sub.3，CH(OH)，C(OH)CH.sub.3，C.dbd.CH.sub.2，CO或O；m为0或1，n为0, 1或2，以及它们的药用盐和生物降解酯，是治疗动脉粥样硬化和不稳定性心绞痛以及预防经皮血管腔成形术后再闭塞的血栓素A.sub.2拮抗剂，尤其是与血栓素合成酶抑制剂结合使用时。
• US5618941A
  申请人：——

  公开号：US5618941A

  公开（公告）日：1997-04-08
• Thromboxane modulating agents. 4. Design and synthesis of 3-(2-[{(4-chlorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid derivatives as potent thromboxane receptor antagonists
  作者：Kevin N. Dack、Roger P. Dickinson、Clive J. Long、John Steele

  DOI：10.1016/s0960-894x(98)00242-x

  日期：1998.8

  The design of a series of thromboxane receptor antagonists based on 3-(2-[(4-chlorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid (1) is described. Addition of an arylmethyl group at the 5-position of 1 gave exceptionally potent agents in vitro and in vivo, with 13a (UK-147,535) giving complete blockade of the TxA(2) receptor for greater than 12 hours in dogs, following all oral dose of 0.1 mg/kg. (C) 1998 Elsevier Science Ltd. All rights reserved.